Janssen Pharmaceutica Nv

Aaron Nathaniel Patrick

Olivier Alexis Georges Querolle

Vineet Pande

Daniel Jason Krosky

Barbara Herkert

Patrick Rene Angibaud

Patrick René Angibaud

James Patrick Edwards

Isabelle Noëlle Constance Pilatte

Virginie Sophie Poncelet

Wei Cai

Zhao-Kui Wan

Yingtao Liu

Liqiang Fu

Xuedong Dai

Barbara Morschhäuser Geb Herkert

Linglong Kong

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Spiro bicyclic inhibitors of menin-MLL interaction

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes. 

Azepane inhibitors of menin-MLL interaction

Provided are compounds of Formula (I), pharmaceutical compositions comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes. 

Exo-aza spiro inhibitors of menin-MLL interaction

The present invention relates to compounds of formula (I): wherein the variables have the meaning defined in the Specification. The compounds according to the present invention are useful for therapy and/or prophylaxis in a mammal, and in particular to spiro bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to fused bicyclic compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Fused bicyclic inhibitors of menin-MLL interaction

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to azepane compounds, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, myelodysplastic syndrome (MDS) and diabetes.

Growing community of inventors

Doylestown, PA, United States of America

Aaron Nathaniel Patrick